MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
CNTX — Context Therapeutics Inc. Common Stock
NasdaqContext Therapeutics Inc. Common Stock
$0.31
-0.00(-1.49%)
- O
- 0.31
- H
- 0.32
- L
- 0.30
- V
- 315.04K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About CNTX
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateOct 20, 2021
Employees15
Stock ExchangeNasdaq
Ticker SymbolCNTX
Key Financial Statistics
| Market Cap | $31.76M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $0.30 - $3.62 |
| 52-Week Avg Volume | 1.47M |
| VWAP | $0.31 |
| Transactions | 1,453 |
| Total Recorded Bars | 1,245 days |